26 September 2024
Braveheart Investment Group plc
("Braveheart" the "Company" or the "Group")
Appointment of Braveheart representative to the Board of Autins Group plc
Braveheart Investment Group plc (AIM: BRH) announces that Dr Qu Li (Non-Executive Director of Braveheart) has been appointed as a Non-Executive Director to the Board of Autins Group plc ("Autins"). Braveheart holds 26.95% per cent. of the issued share capital of Autins and Dr Qu Li has been appointed to act as a representative of Braveheart on the Board of Autins.
As part of Dr Qu Li's appointment to the Board of Autins, Braveheart, Autins, and the nominated adviser to Autins have all entered into a relationship agreement (the "Relationship Agreement"). The Relationship Agreement is to ensure that Autins is capable of carrying on its business independently of Braveheart at all times, and that the costs associated with Qu Li's appointment and tenure as a Director of Autins will be borne by Braveheart.
Trevor Brown, CEO of Braveheart, commented:
"It is three years since we first invested in Autins. Over the ensuing months, as we got to know Autins and its Board, we became convinced that a bright future lay ahead for the company as conditions in the global automative market normalized after the shock of COVID. Qu Li has a deep knowledge of the sector built over many years and we believe that her appointment will prove beneficial to both Boards."
Braveheart Investment Group plc |
Tel: 01738 587555 |
Trevor Brown, Chief Executive Officer Viv Hallam, Executive Director |
|
|
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
James Reeve / George Payne |
|
|
|
Peterhouse Capital Limited (Joint Broker) |
Tel: 020 7469 0936 |
Duncan Vasey / Lucy Williams |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.